Latest Breaking News On - Oncoquest pharmaceuticals inc - Page 1 : vimarsana.com
Dual Corp appoints Rha as CEO
koreatimes.co.kr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreatimes.co.kr Daily Mail and Mail on Sunday newspapers.
OncoQuest Pharmaceuticals Inc Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share this article
TSX Venture: QPT
EDMONTON, AB, June 1, 2021 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ( Quest or the Company ) announces that clinical investigators working with OncoQuest Pharmaceuticals, Inc. ( OQP ) lead clinical candidate oregovomab, will be making two presentations as part of the American Society of Clinical Oncology (ASCO) conference proceedings. OQP acquired oregovomab from OncoQuest Inc., one of the equity investee companies (45%) of Quest PharmaTech Inc.
The first presentation by Dr. Angeles Alvarez Secord, Principal Investigator and Associate Director of Clinical Research at Duke Cancer Institute of Duke University will update the research community on progress with the ongoing FLORA 5 phase III clinical study of front-line carboplatin-paclitaxel-oregovomab chemotherapy. This double blind and placebo con
Quest Provides Update to Immunotherapy Asset Transfer Between OncoQuest Inc and OncoQuest Pharmaceuticals Inc
newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.
Share:
TSX Venture: QPT
EDMONTON, AB, Jan. 5, 2021 /CNW/ - Quest PharmaTech Inc. (TSXV:QPT) ( Quest ) provides update to its June 4, 2020 news release to announce that one of its equity investee companies, OncoQuest Inc. ( OncoQuest ), completed the transfer of the immunotherapy technology assets to OncoQuest Pharmaceuticals, Inc, a KOSDAQ traded company ( OQP , 078590.KQ) on November 7, 2020. However, due to COVID-19 related Korean courts restrictions, final payment of 65,229,709 shares of OQP to OncoQuest has been delayed by one month from December 31, 2020 to January 31, 2021. In addition, a 6 month extension has been added for redemption of US$62.5 million of the Convertible Bonds which may now be redeemed for cash not later than June 30, 2021 and could be used by OncoQuest, in part, to pay for the costs of the transaction, including income taxes. OncoQuest has already received US$125 million worth of Convertible Bonds including the above mentioned US$62.5 million Convertible